GlaxoSmithKline

From Wikispooks
Revision as of 09:12, 25 May 2019 by Robin (talk | contribs) (Created page with "{{group |wikipedia=https://en.wikipedia.org/wiki/GlaxoSmithKline |constitutes=big pharma |leaders= |logo=GSK_logo_svg.svg |twitter= |start= December 2000 |headquarters=980 Gre...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Group.png GlaxoSmithKline  
(Big pharma)Rdf-entity.pngRdf-icon.png
File:GSK logo svg.svg
FormationDecember 2000
Headquarters980 Great West Rd, Brentford, London, UK
Interest ofJohn Buse, Human Genome Sciences, Tachi Yamada
Member ofAlliance for Biosecurity, European Policy Centre, Friends of Europe
Founder ofGalvani Bioelectronics
SubpageGlaxoSmithKline/Board
GlaxoSmithKline/CEO
GlaxoSmithKline/Director

 

An event carried out

EventLocationDescription
Foster child drug trialsNew York
US
In the nightmarish, surreal world of pediatric clinical trials, infants, toddlers, children and teenagers in New York and around the United States are forced to ingest dangerous, toxic pharmaceuticals, arranged by the National Institutes of Health and Big Pharma.

 

Related Quotation

PageQuoteAuthorDate
Warren Buffett“In the pharmaceutical world of economic durable competitive advantages, having a patent on a best-selling drug is about as good as it gets. The next best thing is having a monopoly on selling a country’s national health program the vaccines it needs for its childhood inoculation programs. Both of these businesses are hugely profitable and GSK (GlaxoSmithKline) excels in both these categories.

The vaccine business is particularly attractive because an individual shot (or jab) costs GSK approximately $1.50 to manufacture and it sells to national vaccine programs for approximately $9 a shot. That gives GSK a net profit of approximately $7.50 a shot. This markup gives GSK a very healthy profit margin that improves with each and every new disease that the company develops a vaccine for. Consider this: GSK's profits rose 10% with the 2009 Swine Flu outbreak—a disease for which the company had a state-of-the-art vaccine ready to inoculate the masses.

In addition to its patents and the durable competitive advantage GSK has with the vaccines, it also established the relationships with the world's governments, and it has the financial capital to create, manufacture, and sell vaccines on a world scale. If you were in charge of the health of a nation's 30 million-plus children, who would you buy your vaccines from? Every year? Year after year? You’d pick the biggest and the best. There are only four pharmaceutical giants that control most of the vaccine production in the world and GSK is one of them.

There is another component to the vaccine equation that also spells BIG MONEY: Every year, women all over the world give birth to approximately 133 million new babies, 4.3 million babies in the U.S. alone. With the United States Centers for Disease Control (CDC) recommending that children aged birth through six receive 34 individual vaccine shots/jabs, that means the market for those 34 vaccine shots/jabs increases every year by 4.3 million in just the U.S. alone. This in turn means that the vaccine manufacturers selling in the U.S. have the potential to earn a profit of $1.09 billion every year (4.3 million x 34 x $7.50 = $1.09 billion). Consider the number of yearly vaccines worldwide and the numbers are staggering—approximately $34 billion a year (133 million x 34 x $7.50 = $33.9 billion). After ten years, in the U.S. alone, vaccine manufacturers will see more than $10 billion in net profit. On a world scale, the number jumps to a potential $340 billion in profits.

And wait, it gets even better. With the invention of each new vaccine comes a patent that is good for twenty years and guarantees that no one else can make the vaccine. In other words, the company has a monopoly.

Even when the patents expire, other companies rarely step into the market because the major manufacturers have a permanent relationship with the government health departments of the world. This enables manufacturers to continue making the same vaccines year after year while maintaining their large profit margins even after their patents have expired.

And last but not least, vaccine manufacturers in the US are completely immune from lawsuits. Back in the 1980s several bad batches of vaccines injured so many children that the resulting successful lawsuits threatened to bankrupt the manufacturers, so the manufacturers lobbied a bill through Congress making them a protected class.”
Warren Buffett
Mary Buffett
2011

 

Employees on Wikispooks

EmployeeJobAppointedEndDescription
Paul GirolamiCEOApril 19801986Company still called Glaxo
Paul GirolamiChairman10 December 1985November 1994Company still called Glaxo
Jan LeschlyChief Executive and Director of SmithKline Beecham1994May 2000Attended 3 Bilderberg meetings, in 1998, 1999 and 2002.
Richard Sykes (Big Pharma)Chairman19972001
Patrick VallancePresident of R & D20122018
Patrick VallanceHead of drug discovery2006

 

Related Document

TitleTypePublication dateAuthor(s)Description
Document:Why Barnard Castleblog post24 May 2020Craig MurrayOn 12 April 2020 Dominic Cummings was seen in Castle Barnard during lockdown. Two days later, GSK of Barnard Castle signed an agreement to develop and manufacture a vaccine with Sanofi of France.
Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.


References


57px-Notepad icon.png This is a page stub. Please add to it.